Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2021 08:02 ET | Source: Nkarta, Inc.

Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
December 13, 2021 16:02 ET | Source: Nkarta, Inc.

Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
November 12, 2021 07:15 ET | Source: Nkarta, Inc.

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
November 10, 2021 16:01 ET | Source: Nkarta, Inc.

Nkarta Reports Third Quarter 2021 Financial Results and Business Update

Initial data expected in 1H 2022 from Phase 1 clinical trial of NKX101 in AML and MDSSuccessful dosing of NKX019 in patients with B cell malignancies; initial Phase 1 clinical trial data expected in...
November 04, 2021 08:04 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
October 07, 2021 16:01 ET | Source: Nkarta, Inc.

Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs

First patients dosed in Phase 1 clinical trial evaluating NKX019 in CD19+ advanced B cell malignanciesInitial data from the NKX019 clinical trial expected in 2022Initial data from Phase 1 clinical...
October 01, 2021 08:08 ET | Source: Nkarta, Inc.

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

Data support potential clinical applications of CRISPR/Cas9 genome engineering, CD70 chimeric antigen receptor (CAR) targeting, and donor selection algorithms in next generation NK cell development...
September 14, 2021 08:32 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
August 12, 2021 16:02 ET | Source: Nkarta, Inc.

Nkarta Reports Second Quarter 2021 Financial Results and Business Progress

Initial data from NKX101 clinical trial expected by end of 2021NKX019 patient dosing expected to start in 2H 2021Collaboration with CRISPR Therapeutics to develop gene-edited cell therapiesNew lease...
July 14, 2021 07:00 ET | Source: Nkarta, Inc.

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

88,000 square foot facility in South San Francisco will support scaled manufacturing of Nkarta’s engineered NK cell therapy candidates, and be home to company headquartersPlanned production expansion...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right